| +46 8 791 66 40

IRW Consulting has, for more than 20 years, positioned itself as a smooth and efficient full-service partner when everything from small biotech companies to the largest players in the pharmaceutical industry are conducting clinical trials or need help to analyze their studies.

The way to get a new product on the market in the life science sector can be long and pretentious, but it can be somewhat easier if you are ally with an effective partner to plan, execute and analyze the necessary clinical trials. And in the Nordics we are actually better geared than so many other places. Partly through a number of competent hospitals and a well-structured patient group, partly because of the Nordic-based consulting company IRW Consulting, who specializes in planning, implementing and reporting clinical studies of pharmaceuticals and technical tools for the healthcare industry.

“As we are a full service company, we can handle all parts of the process. We have activities and customers all over the world, but our specialty is projects here in the Nordic countries, and we have offices in all the Nordic capitals, so we can be close to the process and advise on local authority requirements and the like,” explains CEO Ola Jeppsson.

Ola Jeppsson, CEO, IRW Consulting

Strong in the Nordic region

The strong position in the Nordic region and an attention to new working methods make IRW something unique on the market. In combination with the extensive competence and infrastructure in the Nordic health services, IRW is therefore an attractive cocktail for the customers, which among other things includes the big pharma companies that typically need consultancy assistance in their own organization when, for example, new therapies have to be examined. Small and medium-sized companies in the biotech and pharmaceutical industries, on the other hand, often need IRW’s full service consultant capabilities.

“You are always in safe hands with us, because regardless of the scope of the project, we can tailor the right solution. A good example of one of our projects is an ongoing Phase II study in ophtalmology with approx. 150 patients in six countries. But we can easily scale both up and down,” says Ola Jeppsson.

For many years, otherwise, the tendency was that clinical trials was placed outside Europe, but now Ola Jeppsson and IRW are actually experiencing a reverse trend.

“We are experiencing growth in both Stockholm and Copenhagen, but we also have the advantage that we have been involved in this business for more than 20 years, so we have a number of highly experienced employees. At the same time, we have a size that makes us flexible and easy to work with, because there is never far to decision makers”

Digitization ensures better quality

The development within both life science and treatment of patient data is very strong these years, and this benefits customers when developing new products, says Ola Jeppsson.

“The industry has been a bit conservative and slow to adopt new methods such as digitization, but it has turned, so we see a rapid development. We believe that it is just around the corner, because there is a great need to streamline the collection of patient data. As it is today, we go a detour, but in the long run it will be easier. At the moment, we see that the medical record system is growing, and before long we hope to be able to retrieve data directly from digital records.”

However, digitization is not only a means of efficiency improvement, it is also a tool to ensure the very main purpose of the clinical studies, namely, a reliable study of high quality.

“In our work, it is essentially not whether the specific drug works or not. It is about planning and completing the study as correctly as possible and thereby achieving the best possible result,” concludes Ola Jeppsson.

  Interview by Kåre Peitersen